Durgical
EN
Open the app

Spotting familial hypercholesterolaemia

  • Diagnostic approach

One in about 250 people is born with very high LDL. Untreated, many have heart attacks in their 30s to 50s; found early, they can live a normal life.

Updated

What it is

Familial hypercholesterolaemia (FH) is an inherited, autosomal dominant disorder of LDL clearance, most often from variants in the LDL receptor gene (LDLR), less often in APOB or gain-of-function PCSK9. Heterozygous FH affects about 1 in 250 people and usually gives LDL of 190 mg/dL or more in adults from birth; homozygous FH is rare and gives LDL usually above 500 mg/dL with heart disease in childhood. The diagnosis rests on LDL, personal and family history, physical signs and, when available, genetic testing, often scored with the Dutch Lipid Clinic Network criteria.

What to know

  • Suspect FH with LDL of 190 mg/dL (4.9 mmol/L) or more in an adult, or 160 mg/dL (4.1 mmol/L) or more in a child, after secondary causes are excluded.
  • Dutch Lipid Clinic Network criteria in principle: points for family history, premature coronary disease, tendon xanthomas, arcus before 45, LDL level and a causal variant.
  • Dutch score: more than 8 definite, 6–8 probable, 3–5 possible, under 3 unlikely; a causal variant or tendon xanthomas alone score highly.
  • Tendon xanthomas (Achilles, hand extensor tendons) are almost specific for FH; xanthelasma is common and non-specific.
  • Arcus cornealis before about 45 suggests FH; in older people it is common and meaningless.
  • Premature coronary disease in the family: a male first-degree relative before 55 or a female before 60.
  • Each child of a heterozygous parent has a 50% chance of inheriting FH.
  • Risk calculators underestimate risk in FH; treat with a high-intensity statin, then ezetimibe and PCSK9-targeted therapy to reach a 50% fall and the risk target.

Step-by-step approach

  1. Find the index case: LDL of 190 mg/dL or more, premature coronary disease, or tendon xanthomas.
  2. Exclude secondary causes: hypothyroidism, nephrotic syndrome, cholestasis and drugs.
  3. Take a three-generation family history of LDL, early heart attacks and sudden death.
  4. Examine Achilles and hand extensor tendons, eyelids and corneas.
  5. Score the Dutch criteria; offer genetic testing when FH is probable or definite and testing is available.
  6. Treat at once: lifestyle plus a high-intensity statin; add ezetimibe and then PCSK9-targeted therapy as needed.
  7. Start cascade testing: LDL (and the family variant, if known) in all first-degree relatives, then widen.
  8. Screen children of affected parents from about age 2; consider a statin from about 8–10 years.

FH and its look-alikes

FeatureHeterozygous FHPolygenic hypercholesterolaemiaFamilial combined hyperlipidaemiaSecondary (hypothyroid, nephrotic)
LDLUsually 190 mg/dL or more from childhoodRaised, usually less extremeRaised or normal; changes over timeRaised, appears with the disease
TriglyceridesUsually normalUsually normalOften raisedNormal or raised
Family patternHalf of first-degree relatives, high LDLClusters, no clear patternRelatives with different lipid patternsNone
Tendon xanthomasOftenNoNoNo (cholestasis gives other xanthomas)
Genetic testLDLR, APOB or PCSK9 variantMany small-effect variantsPolygenic, no single testNot needed; treat the cause

Keys to the differential

  • Every adult with LDL of 190 mg/dL or more deserves a thought about FH, a family history and an offer to test the family.
  • Children with FH are often found by testing a parent; universal childhood lipid screening also finds them.
  • Women with FH should plan pregnancies; statins are stopped before conception and resumed after breastfeeding.
  • Homozygous FH needs specialist care from diagnosis: combined drugs, lipoprotein apheresis and newer agents such as evinacumab or lomitapide.

Next step / Initial management

  • Repeat LDL with TSH, glucose, creatinine, urine protein and liver tests to exclude secondary causes.
  • Score the Dutch criteria; offer genetic testing for probable or definite FH where available.
  • Start a high-intensity statin, add ezetimibe, then a PCSK9 inhibitor or inclisiran if LDL stays above target.
  • Refer to a lipid clinic or endocrinology every probable or definite FH, every child with suspected FH, and urgently any LDL above 500 mg/dL (possible homozygous FH).

Common traps

  • A low calculated 10-year risk means a person with FH can wait: lifelong high LDL makes calculators underestimate risk, so FH is treated regardless of the score.
  • Xanthelasma points to FH: it is common and non-specific, often with normal lipids; tendon xanthomas are the sign that points to FH.
  • A negative genetic test excludes FH: a causal variant is not found in a sizeable share of clinical FH, so clinical criteria still guide treatment and cascade testing.
  • Children are too young for lipid testing or statins: atherosclerosis starts in childhood in FH, and screening from about 2 and statins from about 8–10 years shorten the LDL exposure.
  • Finding FH is about one patient: it is dominant, so half of first-degree relatives are affected and cascade testing is the most efficient way to find them.

Test yourself

Think of the answer, then tap the question to see it.

A 38-year-old man has LDL 260 mg/dL, thickened Achilles tendons and a father who died at 50 of a heart attack. What is the diagnosis and the next step for his family?

Probable or definite FH by the Dutch criteria. Treat him with a high-intensity statin and cascade-test first-degree relatives, including his children.

A 7-year-old's mother has genetically confirmed FH. When and how should the child be tested?

Now: test LDL and the family variant. With a 50% chance of FH, screening from about age 2 allows statins from about 8–10 years.

A 70-year-old has arcus cornealis and an LDL of 130 mg/dL. Does the arcus suggest FH?

No: arcus is common with age. It suggests FH only before about 45 years, and his LDL is not in the FH range.

Why are risk calculators not used to decide treatment in FH?

Because they assume an ordinary lifetime LDL; FH patients have had high LDL since birth, so calculators underestimate their risk.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of endocrinology

Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.

Sources: Familial Hypercholesterolemia (StatPearls (NCBI Bookshelf), 2022); Hypercholesterolemia (StatPearls (NCBI Bookshelf), 2023); Xanthoma (StatPearls (NCBI Bookshelf), 2026); Familial Combined Hyperlipidemia (StatPearls (NCBI Bookshelf), 2023); PCSK9 Inhibitors (StatPearls (NCBI Bookshelf), 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.